Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cidara Therapeutics (CDTX) Accounts Payables: 2017-2024

Historic Accounts Payables for Cidara Therapeutics (CDTX) over the last 8 years, with Dec 2024 value amounting to $3.6 million.

  • Cidara Therapeutics' Accounts Payables rose 46.65% to $4.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.4 million, marking a year-over-year increase of 46.65%. This contributed to the annual value of $3.6 million for FY2024, which is 4.35% down from last year.
  • Cidara Therapeutics' Accounts Payables amounted to $3.6 million in FY2024, which was down 4.35% from $3.8 million recorded in FY2023.
  • Cidara Therapeutics' Accounts Payables' 5-year high stood at $4.6 million during FY2020, with a 5-year trough of $1.3 million in FY2021.
  • Moreover, its 3-year median value for Accounts Payables was $3.6 million (2024), whereas its average is $2.9 million.
  • In the last 5 years, Cidara Therapeutics' Accounts Payables crashed by 71.52% in 2021 and then skyrocketed by 160.68% in 2023.
  • Yearly analysis of 5 years shows Cidara Therapeutics' Accounts Payables stood at $4.6 million in 2020, then slumped by 71.52% to $1.3 million in 2021, then increased by 11.22% to $1.4 million in 2022, then surged by 160.68% to $3.8 million in 2023, then decreased by 4.35% to $3.6 million in 2024.